CN101389346A - 人glp-1模拟体、组合物、方法和用途 - Google Patents

人glp-1模拟体、组合物、方法和用途 Download PDF

Info

Publication number
CN101389346A
CN101389346A CNA200580049931XA CN200580049931A CN101389346A CN 101389346 A CN101389346 A CN 101389346A CN A200580049931X A CNA200580049931X A CN A200580049931XA CN 200580049931 A CN200580049931 A CN 200580049931A CN 101389346 A CN101389346 A CN 101389346A
Authority
CN
China
Prior art keywords
glp
seq
polypeptide
analogue body
disappearance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200580049931XA
Other languages
English (en)
Chinese (zh)
Inventor
K·T·奥奈尔
K·皮查
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of CN101389346A publication Critical patent/CN101389346A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CNA200580049931XA 2005-03-28 2005-12-22 人glp-1模拟体、组合物、方法和用途 Pending CN101389346A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2005097175 2005-03-28
USPCT/US2005/097175 2005-03-28

Publications (1)

Publication Number Publication Date
CN101389346A true CN101389346A (zh) 2009-03-18

Family

ID=38256744

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200580049931XA Pending CN101389346A (zh) 2005-03-28 2005-12-22 人glp-1模拟体、组合物、方法和用途

Country Status (12)

Country Link
EP (1) EP1871811A4 (enExample)
JP (1) JP2008546373A (enExample)
KR (1) KR20080005378A (enExample)
CN (1) CN101389346A (enExample)
AU (1) AU2005339797A1 (enExample)
BR (1) BRPI0520168A2 (enExample)
CA (1) CA2603359A1 (enExample)
CR (1) CR9481A (enExample)
IL (1) IL186307A0 (enExample)
MX (1) MX2007011975A (enExample)
NO (1) NO20075272L (enExample)
WO (1) WO2007081302A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111574583A (zh) * 2020-04-10 2020-08-25 上海海路生物技术有限公司 蛋白复性试剂及其应用
CN120741086A (zh) * 2024-07-26 2025-10-03 荣耀终端股份有限公司 模拟人体组织液及其制备方法和应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200843794A (en) * 2006-12-21 2008-11-16 Centocor Inc Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046380A2 (en) * 1999-02-08 2000-08-10 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
NZ525577A (en) * 2000-12-07 2005-05-27 Lilly Co Eli Glucagon-Like Peptide 1 heterologous fusion proteins for the treatment of non-insulin dependent diabetes mellitus
JP2006504406A (ja) * 2002-06-28 2006-02-09 セントカー・インコーポレーテツド 哺乳動物のｃｈ１欠失ミメティボディ、組成物、方法および使用
AU2003256336A1 (en) * 2002-06-28 2004-01-19 Centocor, Inc. Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses
EP1644416A4 (en) * 2003-06-30 2007-08-29 Centocor Inc ANTI-TARGET AND GENETICALLY MODIFIED IMMUNOGLOBULIN-DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
AU2005231359A1 (en) * 2004-03-31 2005-10-20 Centocor, Inc. Human GLP-1 mimetibodies, compositions, methods and uses

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111574583A (zh) * 2020-04-10 2020-08-25 上海海路生物技术有限公司 蛋白复性试剂及其应用
CN120741086A (zh) * 2024-07-26 2025-10-03 荣耀终端股份有限公司 模拟人体组织液及其制备方法和应用

Also Published As

Publication number Publication date
WO2007081302A3 (en) 2008-11-13
EP1871811A4 (en) 2009-07-22
EP1871811A2 (en) 2008-01-02
BRPI0520168A2 (pt) 2009-04-22
AU2005339797A1 (en) 2007-07-19
NO20075272L (no) 2007-12-28
KR20080005378A (ko) 2008-01-11
CR9481A (es) 2009-01-14
MX2007011975A (es) 2008-03-14
WO2007081302A2 (en) 2007-07-19
CA2603359A1 (en) 2007-07-19
JP2008546373A (ja) 2008-12-25
IL186307A0 (en) 2008-01-20

Similar Documents

Publication Publication Date Title
US8071103B2 (en) Pharmaceutical composition comprising a human GLP-1 mimetibody
US20070128193A1 (en) GLP-1 agonists, compositions, methods and uses
US20070135338A1 (en) Human GLP-1 mimetibodies, compositions, methods and uses
US7833531B2 (en) Method for treating insulin sensitivity by long-acting GLP-1 receptor mimetibody agonists
US7241733B2 (en) Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses
EP1675579A2 (en) Human epo mimetic hinge core mimetibodies, compositions, methods and uses
CN101389346A (zh) 人glp-1模拟体、组合物、方法和用途
CN101426519A (zh) 人glp-1模拟体、组合物、方法和用途
EP1968645A2 (en) Human glp-1 mimetibodies and compositions for treating obesity and related disorders, methods and uses

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090318